Brief: Quince Therapeutics Completes Enrollment In Pivotal Phase 3 NEAT Clinical Trial In Ataxia-Telangiectasia
16/07/2025 13:06
July 16 (Reuters) - Quince Therapeutics Inc QNCX.O: QUINCE THERAPEUTICS COMPLETES ENROLLMENT IN PIVOTAL PHASE 3 NEAT CLINICAL TRIAL IN ATAXIA-TELANGIECTASIA QUINCE THERAPEUTICS INC - EXPECTS NEAT TRIAL RESULTS IN Q1 2026 QUINCE THERAPEUTICS INC - PLANS NDA SUBMISSION TO FDA IN H2 2026 Source text: ID:nBw6XKDrna Further company coverage: QNCX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IRulya Therapeutics
See all newsBrief: Quince Therapeutics - Changes Name To Irulya Therapeutics
Brief: Quince Therapeutics - Appoints Brigette Roberts As CEO Effective October 8, 2026
Quince Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Quince Therapeutics Reports Second Quarter 2026 Financial Results And Corporate Update
Quince Therapeutics Q2 net loss widens on acquisition charges